SCHEMBL6315348

SCHEMBL6315348

COc1ccc(-c2noc(N)c2C(=O)NCc2ccc(OC(F)(F)F)cc2)cn1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.46
CDK2 P24941 1/20 0.45
GSK3B P49841 1/20 0.45
MAPT P10636 2/20 0.44
PDE2A O00408 1/20 0.44
ALDH1A1 P00352 1/20 0.44
EPHX2 P34913 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
HDAC1 Q13547 1/20 0.42
LMNA P02545 1/20 0.42
ABL1 P00519 1/20 0.42
PPARD Q03181 2/20 0.42
VNN1 O95497 1/20 0.41
GCGR P47871 1/20 0.41
POLB P06746 1/20 0.41
PPARA Q07869 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316520 0.91 MAPT (0.52) CDK2GSK3BMAPTALDH1A1HDAC1
SCHEMBL6315541 0.89 GSK3B (0.46) CDK2GSK3BMAPTALDH1A1HDAC1
SCHEMBL6323365 0.87 CDK2 (0.47) CDK2GSK3BMAPTALDH1A1HDAC1
SCHEMBL6324039 0.86 ALDH1A1 (0.52) CDK2GSK3BMAPTALDH1A1HDAC1
SCHEMBL6318699 0.85 TACR1 (0.44) CDK2GSK3BMAPTALDH1A1HDAC1
SCHEMBL6323629 0.84 MET (0.44) CDK2GSK3BMAPTALDH1A1HDAC1
SCHEMBL6321897 0.83 SMN1; SMN2 (0.47) ALDH1A1HDAC1LMNAPOLB
SCHEMBL6323454 0.83 ALDH1A1 (0.49) ADRB2MAPTPDE2AALDH1A1EPHX2
SCHEMBL6316803 0.82 ROCK2 (0.46) MAPTALDH1A1POLB
SCHEMBL6323609 0.82 ADORA2A (0.48) CDK2GSK3BALDH1A1HDAC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 ADRB2 3527/4885CDK2 284/4885GSK3B 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.